Insulet Corp.

PODD

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001145197

A

strongest fifth of 305 graded peers in healthcare

rank 46 of 305; percentile 14.8; sampling error 2.8 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B percentile 34.7
Solvency	B/C percentile 39.2
Growth and financing	B percentile 33.6
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $3.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: short runway, distress
Inputs computable	9 of 13
Graded from	filings received through Feb 18, 2026 278 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$133.28 2026-11-20; market equity $9.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 18, 2026

Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod® 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH® Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Classic Omnipod"). We also produce pods for Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen's Neulasta to help reduce the risk of infection after intense chemotherapy. Diabetes is a chronic, life-threatening disease for which there is no known cure.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 34.7						
Gross profitability	60.8%	32.8%		16.2	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

prior invested-capital observation is 731 days earlier					
Accruals ratio	(10.3%)	(6.7%)	39.9	756	2025-12-31
Gross margin stability, five years	2.7 pts	2.8 pts	47.9	237	2025-12-31
Solvency, sleeve percentile 39.2					
Altman Z double-prime	4.78	0.31	19.7	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31					
Interest coverage	not computable	(3.61x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.81x	2.68x	58.7	781	2025-12-31
Growth and financing, sleeve percentile 33.6					
Revenue growth, three-year compound	36.9%	9.6%	17.5	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	(8.1%)	33.9%	74.0	101	2025-12-31
Asset growth, three years	12.3%	3.2%	28.4	663	2025-12-31
Net share issuance, one year	0.2%	1.6%	14.4	626	2026-02-11

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
41	Orthopediatrics Corp. (KIDS)	13.2	A	
42	Utah Medical Products Inc. (UTMD)	13.5	A	fortress balance sheet
43	Procept BioRobotics Corp. (PRCT)	13.8	A	fortress balance sheet
44	Resmed Inc. (RMD)	14.1	A	fortress balance sheet
45	PRO DEX Inc. (PDEX)	14.5	A	
46	Insulet Corp. (PODD)	14.8	A	
47	Ardelyx, Inc. (ARDX)	15.1	A	
48	Lantheus Holdings, Inc. (LNTH)	15.5	A	
49	Harrow, Inc. (HROW)	15.8	A	late filer
50	TG Therapeutics, Inc. (TGTX)	16.1	A	
51	Natures Sunshine Products Inc. (NATR)	16.4	A	fortress balance sheet

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(58.3%)	(1.7%)	12
Distance from 52-week high	(60.5%)	(33.0%)	26
EBIT to enterprise value	5.1%	0.5%	77
Free cash flow yield	4.1%	0.6%	72
Book value to price	0.17	0.29	34
Sales to price	0.29	0.38	42

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	4.9%	13.5%	37
Relative strength against the sector, log excess return	(1.05)	(0.19)	12
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 6 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	19 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$203.7M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.9B	2025-12-31	2026-02-18	10-K	26-000028
2	assets	us-gaap:Assets	$3.2B	2025-12-31	2026-02-18	10-K	26-000028
3	operating income	us-gaap:OperatingIncomeLoss	$51.5M	2020-12-31	2023-02-24	10-K	23-000020
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$9.7M	2020-12-31	2021-02-24	10-K	21-000009
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$2.9M	2020-12-31	2023-02-24	10-K	23-000020
6	total debt	us-gaap:LongTermDebt	$1.1B	2020-12-31	2022-02-24	10-K	22-000012
7	book equity	us-gaap:StockholdersEquity	$603.6M	2020-12-31	2024-02-23	10-K	24-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$907.2M	2020-12-31	2021-02-24	10-K	21-000009
9	total debt	us-gaap:LongTermDebt	$592.0M	2018-12-31	2019-02-26	10-K	19-000003
10	book equity	us-gaap:StockholdersEquity	$212.1M	2018-12-31	2022-02-24	10-K	22-000012
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$113.9M	2018-12-31	2020-02-26	10-K	20-000004
12	net income	us-gaap:NetIncomeLoss	$247.1M	2025-12-31	2026-02-18	10-K	26-000028
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$569.3M	2025-12-31	2026-02-18	10-K	26-000028
14	assets	us-gaap:Assets	$3.1B	2024-12-31	2026-02-18	10-K	26-000028
15	revenue	us-gaap:Revenues	$2.7B	2025-12-31	2026-02-18	10-K	26-000028
16	gross profit	us-gaap:GrossProfit	$1.4B	2024-12-31	2026-02-18	10-K	26-000028
17	revenue	us-gaap:Revenues	$2.1B	2024-12-31	2026-02-18	10-K	26-000028
18	gross profit	us-gaap:GrossProfit	$1.2B	2023-12-31	2026-02-18	10-K	26-000028
19	revenue	us-gaap:Revenues	$1.7B	2023-12-31	2026-02-18	10-K	26-000028
20	gross profit	us-gaap:GrossProfit	$805.6M	2022-12-31	2025-02-21	10-K	25-000007
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.1B	2022-12-31	2023-02-24	10-K	23-000020
22	gross profit	us-gaap:GrossProfit	$752.1M	2021-12-31	2024-02-23	10-K	24-000011
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0B	2021-12-31	2023-02-24	10-K	23-000020
24	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-18	10-K	26-000028
25	current liabilities	us-gaap:LiabilitiesCurrent	$680.1M	2025-12-31	2026-02-18	10-K	26-000028
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$287.4M	2025-12-31	2026-02-18	10-K	26-000028
27	operating income	us-gaap:OperatingIncomeLoss	$473.8M	2025-12-31	2026-02-18	10-K	26-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	book equity	us-gaap:StockholdersEquity	$1.5B	2025-12-31	2026-02-18	10-K	26-000028
29	liabilities	us-gaap:Liabilities	$1.7B	2025-12-31	2026-02-18	10-K	26-000028
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$55.4M	2020-12-31	2023-02-24	10-K	23-000020
31	operating income	us-gaap:OperatingIncomeLoss	$220.1M	2023-12-31	2026-02-18	10-K	26-000028
32	interest expense	us-gaap:InterestExpense	$36.2M	2023-12-31	2024-02-23	10-K	24-000011
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$191.6M	2025-12-31	2026-02-18	10-K	26-000028
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$430.2M	2024-12-31	2026-02-18	10-K	26-000028
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$124.9M	2024-12-31	2026-02-18	10-K	26-000028
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$145.7M	2023-12-31	2026-02-18	10-K	26-000028
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$75.6M	2023-12-31	2026-02-18	10-K	26-000028
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$119.0M	2022-12-31	2025-02-21	10-K	25-000007
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$122.9M	2022-12-31	2025-02-21	10-K	25-000007
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$90.4M	2025-12-31	2026-02-18	10-K	26-000028
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$339.5M	2025-12-31	2026-02-18	10-K	26-000028
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$92.4M	2025-12-31	2026-02-18	10-K	26-000028
43	current assets	us-gaap:AssetsCurrent	$1.9B	2024-12-31	2026-02-18	10-K	26-000028
44	current liabilities	us-gaap:LiabilitiesCurrent	$528.4M	2024-12-31	2026-02-18	10-K	26-000028
45	assets	us-gaap:Assets	$2.6B	2023-12-31	2025-02-21	10-K	25-000007
46	assets	us-gaap:Assets	$2.3B	2022-12-31	2024-02-23	10-K	24-000011
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	70,395,848	2026-02-11	2026-02-18	10-K	26-000028
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	70,226,104	2025-02-13	2025-02-21	10-K	25-000007

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.